- AGEN1884 (CTLA-4) and AGEN2034 (PD-1) show objective clinical responses
- More than 100 patients treated with AGEN1884 and AGEN2034
- Combination trial has commenced in cervical cancer
PR Newswire
LEXINGTON, Mass., May 17, 2018
PR Newswire
LEXINGTON, Mass., May 17, 2018
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey